All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
During the European Society of Hematology (ESH) 2nd How I manage: CAR-T therapies and bispecific antibodies for my patients 2023 Congress, the Lymphoma Hub spoke to Ulrich Jӓger, Medical University of Vienna, Vienna, AT. We asked, What are the key updates from ESH 2nd How I manage: CAR-T therapies and bispecific antibodies?
What are the key updates from ESH: 2nd How I manage: CAR T therapies and bispecific antibodies?
Firstly, Jӓger discusses key topics, including the future of chimeric-antigen receptor T-cell therapy and bispecific antibody treatment, the toxicities involved in these treatments, the potential to combine both treatment options, and how to sequence treatments in specific indications. He also highlights key learnings across all indications from the meet-the-expert sessions and debates held at this congress.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
What was new in aggressive NHL at #ASCO20 and EHA 2020?
Interview with Ulrich Jäger, Medical University of Vienna. We asked, What was new in aggressive non-Hodgkin lymphoma at this year's ASCO and EHA virtual meetings?
Lymphoma Hub Satellite Symposium 2019 | DLBCL - chemotherapy-free regimens - Professor Ulrich Jäger
Professor Ulrich Jäger, Medical University of Vienna, Vienna, AT, summarized that the status of DLBCL treatments, with chemotherapy still firmly the...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox